Related Experiment Videos
Glycemic control and heart disease
1Cardiovascular Nurse Clinician, Alexian Brothers Hospital, Elk Grove Village, Illinois, USA.
Insights
Intensive insulin therapy following acute myocardial infarction (AMI) significantly improves outcomes for diabetic patients. Tight glucose control in diabetes patients after AMI reduces mortality and severe heart failure.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Background:
- Cardiovascular disease is the primary cause of death in diabetic patients, accounting for 80% of fatalities.
- Diabetic patients experiencing acute myocardial infarctions (AMIs) face higher reinfarction rates and increased risk of severe heart failure post-AMI.
- The need for specific therapeutic strategies in diabetic patients post-AMI is critical.
Purpose of the Study:
- To evaluate the efficacy of intensive insulin therapy versus conventional treatment in diabetic patients following AMI.
- To determine the impact of tight glucose control on clinical outcomes and mortality in this patient population.
Main Methods:
- The study involved the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) clinical trial.
- Comparison of intensive insulin therapy with conventional treatment protocols post-AMI.
Main Results:
- Intensive insulin therapy demonstrated a significant benefit in managing diabetic patients after AMI.
- Tight glucose control was directly linked to improved clinical outcomes.
- Mortality rates were reduced in the group receiving intensive insulin therapy.
Conclusions:
- Tight glucose control is essential for improving clinical outcomes and reducing mortality in diabetic patients following AMI.
- The DIGAMI trial provides strong evidence supporting intensive insulin therapy in this high-risk group.
- Diabetic management post-AMI requires specific attention to glucose levels for better patient prognosis.
Abstract:
The leading cause of death among patients with diabetes is cardiovascular disease with approximately 80% of all deaths being attributed to coronary heart disease. Acute myocardial infarctions (AMIs) in patients with diabetes are associated with an increased rate of reinfarction than those without diabetes. Following AMI, patients with diabetes are more likely to develop severe heart failure. The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) clinical trial examined the relationship between intensive insulin and conventional therapy following AMI. Results of the DIGAMI study clearly identify the need for tight glucose control following AMI in improving clinical outcomes and mortality.